革命性的NSCLC治疗:针对EGFR-TKI耐药性的免疫疗法策略
Jin Tian1, Zhiqi Shi2, Lili Zhao1
1Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China.
表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 是EGFR突变非小细胞肺癌 (NSCLC) 的标准. 本综述探讨了免疫检查点抑制剂 (ICI) 作为EGFR-TKI耐药性后的治疗选择.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮肤生长因子受体氨酸激酶抑制剂 (EGFR-TKIs) 是治疗EGFR突变的晚期非小细胞肺癌 (NSCLC) 的首要治疗方法.
- 对EGFR-TKIs的获得性耐药性是先进NSCLC治疗中的重大临床挑战.
- 免疫检查点抑制剂 (ICI) 代表了高级NSCLC的新疗法策略,特别是在缺乏可向分子变化的患者中.
研究的目的:
- 对非小细胞肺癌患者的免疫治疗现状进行审查,这些患者已经对EGFR-TKI产生了耐药性.
- 探索各种免疫疗法策略的有效性和应用,包括单疗法和组合治疗.
主要方法:
- 对研究免疫检查点抑制剂 (ICI) 在NSCLC中EGFR-TKI耐药性的背景下进行的文献综述.
- 分析目前的治疗方法,包括单疗法,与EGFR-TKI结合,化疗和抗血管原剂.
主要成果:
- 在先进的NSCLC管理中,EGFR-TKI耐药性仍然是一个关键问题.
- 免疫检查点抑制剂 (ICI) 在获得对EGFR-TKI耐药性的NSCLC患者中显示出潜在的有效性.
- 目前正在探索涉及ICI和其他药物的组合疗法,以克服耐药性并改善结果.
结论:
- 免疫疗法,特别是免疫检查点抑制剂 (ICI),为EGFR-TKI抗性非小细胞肺癌 (NSCLC) 患者提供了一个有前途的途径.
- 对组合策略的进一步研究对于优化治疗疗效和管理高级NSCLC中耐药性机制至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
